---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-083425"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:13:38.037553+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "medium"
source: SEC EDGAR
---

# Hepion provides corporate presentation; no material new financial or clinical data

## Summary
- Rencofilstat Phase 2b ASCEND-NASH enrolling; AI-POWR platform highlighted.
- Phase 2a HCC trial pending; rencofilstat tested in over 425 subjects to date.
- Cash of $43.0M as of March 31, 2023; IP extends to at least 2031 with PTE.
- Core team previously developed voclosporin (Lupkynis) for lupus nephritis.
- Presentation details pipeline, finance, and management; no new clinical results disclosed.

## SEC filing metadata
- accession: 0001104659-23-083425
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465923083425/0001104659-23-083425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465923083425/tm2321697d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-083425
- JSON: https://secwatch.observer/filing/0001104659-23-083425.json
- Plain text: https://secwatch.observer/filing/0001104659-23-083425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.